| Literature DB >> 25532755 |
Daniel J Buzard1, Thomas O Schrader1, Xiuwen Zhu1, Juerg Lehmann1, Ben Johnson1, Michelle Kasem1, Sun Hee Kim1, Andrew Kawasaki1, Luis Lopez1, Jeanne Moody1, Sangdon Han1, Yinghong Gao1, Jeff Edwards1, Jeremy Barden1, Jayant Thatte1, Joel Gatlin1, Robert M Jones1.
Abstract
Modulators of S1P1 have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P1 chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P1 receptor.Entities:
Keywords: Gilenya®; S1P(1); Sphingosine-1-phosphate
Mesh：
Substances：
Year: 2014 PMID： 25532755 DOI： 10.1016/j.bmcl.2014.11.089
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823